Physician profile
Arash Akhavan
NPI 1013138874
$37,603.56
in general payments reported to CMS, 2019-2025
28 companies · $4,804 in 2025
The $4,804 reported for 2025 was more than what 89% of Dermatology providers received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,812 · 2020: $913 · 2021: $317 · 2022: $868 · 2023: $8,506 · 2024: $18K · 2025: $4,804.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $29K · Food and Beverage: $1,306 · Travel and Lodging: $1,042 · Education: $94.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $29,250.00 |
| Food and Beverage | $1,306.18 |
| Travel and Lodging | $1,041.89 |
| Education | $94.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $31,198.60 | 2019-2025 | Botox |
| Merz North America, INC. | $3,093.23 | 2019-2023 | |
| Allergan, INC. | $696.79 | 2019-2022 | |
| Galderma Laboratories, L.P. | $563.26 | 2019-2023 | Epsolay, Aklief, Oracea |
| Janssen Biotech, INC. | $300.52 | 2019-2025 | Tremfya |
| Lilly USA, LLC | $280.07 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $244.75 | 2021-2025 | Jublia, Cabtreo |
| Novartis Pharmaceuticals Corporation | $173.02 | 2020-2023 | |
| Sun Pharmaceutical Industries INC. | $141.76 | 2019-2025 | Winlevi, Absorica Ld |
| Leo Pharma INC. | $132.96 | 2019-2023 | Adbry |
| Incyte Corporation | $87.57 | 2021-2023 | Opzelura |
| Vyne Pharmaceuticals INC. | $80.48 | 2020-2021 | |
| Regeneron Healthcare Solutions, INC. | $79.59 | 2019-2022 | |
| Mayne Pharma Commercial LLC | $63.60 | 2019-2023 | |
| Almirall LLC | $62.45 | 2020-2023 | Klisyri, Seysara |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $56.56 | 2019-2022 | |
| Amgen INC. | $50.65 | 2023-2024 | Otezla |
| Pfizer INC. | $46.59 | 2019-2022 | |
| Celgene Corporation | $46.24 | 2019 | |
| Medimetriks Pharmaceuticals, INC. | $37.87 | 2019 | |
| Dermavant Sciences, INC. | $25.51 | 2022 | |
| Ucb, INC. | $24.07 | 2021 | |
| Mylan Pharmaceuticals INC. | $21.12 | 2019 | |
| Cipher Pharmaceuticals US LLC | $20.48 | 2025 | Natroba, Spinosad |
| Journey Medical Corporation | $20.18 | 2025 | |
| Botanix Sb INC | $19.32 | 2025 | Sofdra |
| Strata Skin Sciences, INC. | $18.63 | 2025 | Xtrac |
| Promius Pharma LLC | $17.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arash Akhavan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.